Dyne Therapeutics, Inc. (NYSE:DYN) Given Consensus Rating of “Buy” by Brokerages

Shares of Dyne Therapeutics, Inc. (NYSE:DYN) have received an average recommendation of “Buy” from the five research firms that are currently covering the firm, Marketbeat reports. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $26.50.

Several equities research analysts have commented on the stock. StockNews.com began coverage on shares of Dyne Therapeutics in a report on Thursday, August 17th. They issued a “sell” rating on the stock. JPMorgan Chase & Co. upped their target price on Dyne Therapeutics from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 9th. Finally, Chardan Capital reiterated a “buy” rating and set a $20.00 price target on shares of Dyne Therapeutics in a research report on Friday, August 4th.

Dyne Therapeutics Stock Up 3.2 %

Dyne Therapeutics stock opened at $11.77 on Monday. The stock has a 50-day moving average price of $11.15 and a 200 day moving average price of $11.48. The company has a market capitalization of $718.21 million, a price-to-earnings ratio of -3.46 and a beta of 0.14. Dyne Therapeutics has a 52 week low of $8.04 and a 52 week high of $15.63.

Dyne Therapeutics (NYSE:DYN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.81) by ($0.27). Research analysts anticipate that Dyne Therapeutics will post -3.57 EPS for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In related news, insider Richard William Scalzo sold 10,000 shares of Dyne Therapeutics stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $12.03, for a total value of $120,300.00. Following the sale, the insider now owns 43,482 shares of the company’s stock, valued at approximately $523,088.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Dyne Therapeutics news, insider Joshua T. Brumm sold 187,748 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $12.61, for a total transaction of $2,367,502.28. Following the completion of the sale, the insider now directly owns 253,383 shares in the company, valued at approximately $3,195,159.63. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Richard William Scalzo sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $12.03, for a total value of $120,300.00. Following the completion of the transaction, the insider now owns 43,482 shares in the company, valued at approximately $523,088.46. The disclosure for this sale can be found here. Over the last three months, insiders have sold 275,955 shares of company stock valued at $3,529,605. Company insiders own 32.89% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Large investors have recently made changes to their positions in the company. Braidwell LP purchased a new stake in shares of Dyne Therapeutics during the fourth quarter worth $8,729,000. HRT Financial LP purchased a new stake in Dyne Therapeutics during the 4th quarter valued at about $195,000. EcoR1 Capital LLC acquired a new stake in Dyne Therapeutics in the 4th quarter valued at about $26,916,000. Integral Health Asset Management LLC purchased a new position in Dyne Therapeutics in the 1st quarter worth approximately $657,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Dyne Therapeutics by 22.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,123 shares of the company’s stock worth $198,000 after purchasing an additional 3,172 shares during the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.